Table 1.
Patients' characteristics and demographic data
| Characteristic | No. (%) (n=205) |
|---|---|
| Age, median (range, yr) | 60 (32-88) |
| Sex | |
| Male | 76 (37.1) |
| Female | 129 (62.9) |
| Smoking status | |
| Never smokers | 162 (79.0) |
| Former smokers | 23 (11.2) |
| Current smokers | 20 (9.8) |
| Baseline EGFR mutation status | |
| Exon 19 deletions | 111 (54.1) |
| Exon 21 L858R | 83 (40.5) |
| Other mutationsa) | 11 (5.4) |
| First-line TKI | |
| Gefitinib | 94 (45.9) |
| Erlotinib | 98 (47.8) |
| Afatinib | 13 (6.3) |
| Best response of first-line TKI | |
| Stable disease | 29 (14.1) |
| Partial response | 176 (85.9) |
| PFS of first-line TKI | |
| ≤ 11 mo | 107 (52.2) |
| > 11 mo | 98 (47.8) |
| Rebiopsy site | |
| Primary tumor | 68 (33.2) |
| Metastases | 137 (66.8) |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PFS, progression-free survival.
a)
Includes complex mutation.